Khattar Jack A. 4

What Happened
Jack A. Khattar, President, Chief Executive Officer and a director of Supernus Pharmaceuticals, was granted a derivative award of 341,610 shares on February 18, 2026. The Form 4 reports the acquisition at $0.00 (i.e., no cash paid at grant) and lists the transaction as a derivative award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (filed within the typical 2-business-day Form 4 window).
• Reported amount: 341,610 shares; reported price: $0.00 (derivative award).
• Shares owned after the transaction: not specified in the filing.
• Footnote: The option vests in four equal annual installments beginning on February 18, 2027 (per footnote F1).
• Transaction code: A (grant/award/other acquisition) — not a sale or open-market purchase.

Context
This was a derivative grant (an option-style award) that will vest over four years beginning Feb 18, 2027. Such awards are not immediately tradable shares — the economic and tax consequences occur as the award vests and, if applicable, is exercised or settled. The filing is informational and does not, by itself, indicate the insider’s view on the company’s stock.